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Abstract 
Background: Plasmodium falciparum infection can lead to several clinical manifestations ranging from asymptomatic 
infections (AM) and uncomplicated malaria (UM) to potentially fatal severe malaria (SM), including cerebral malaria 
(CM). Factors implicated in the progression towards severe disease are not fully understood.
Methods: In the present study, an enzyme-linked immunosorbent assay (ELISA) method was used to investigate the 
plasma content of several biomarkers of the immune response, namely Neopterin, sCD163, suPAR, Pentraxin 3 (PTX3), 
sCD14, Fractalkine (CX3CL1), sTREM-1 and MIG (CXCL9), in patients with distinct clinical manifestations of malaria. The 
goal of this study was to determine the relative involvement of these inflammatory mediators in the pathogenesis of 
malaria and test their relevance as biomarkers of disease severity.
Results: ROC curve analysis show that children with AM were characterized by high levels of Fractalkine and sCD163 
whereas children with UM were distinguishable by the presence of PTX3 in their plasma. Furthermore, principal 
component analysis indicated that the combination of Fractalkine, MIG, and Neopterin was the best predictor of AM 
condition, while suPAR, PTX3 and sTREM-1 combination was the best indicator of UM when compared to AM. The 
association of Neopterin, suPAR and Fractalkine was strongly predictive of SM or CM compared to UM.
Conclusions: The results indicate that the simultaneous evaluation of these bioactive molecules as quantifiable 
blood parameters may be helpful to get a better insight into the clinical syndromes in children with malaria.
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sTREM-1
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Background
Malaria is a potentially life threatening infection that 
claims 584,000 lives each year [1]. The majority (91 %) of 
deaths are due to Plasmodium falciparum infections and 
occur in sub-Saharan Africa [2]. Malaria presents with a 
wide range of clinical manifestations from asymptomatic 
carriage to mild malarial attack and life threatening 
pathologies, such as severe malaria-associated anaemia, 
acute renal failure, acute respiratory distress syndrome, 
haemoglobinuria, disseminated intravascular coagula-
tion, and cerebral malaria [3, 4]. These clinical syndromes 
are the result of interactions between various host and 
parasite factors, and some parasite strains seem to be 
more virulent than others [5–7]. Of the various host 
factors that may be involved in the determination of 
clinical manifestations of malaria infection, the immuno-
logical status and human genetic background of malaria-
infected individuals seem to play an important role in 
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malaria pathology. Specifically, the types of cytokines 
and chemokines produced by the host are thought to play 
an important role in the progression of uncomplicated 
malaria towards cerebral malaria and other severe and 
complicated pathological manifestations. For instance, 
increased plasma levels of pro-inflammatory tumour 
necrosis factor (TNF), interferon-gamma (IFN-γ), and 
interleukin-1 beta (IL-1β) [8, 9], as well as decreased 
levels of anti-inflammatory cytokines, such as IL-10 and 
transforming growth factor beta 1 (TGF-β1) [9–11], are 
hallmarks of severe malaria.
Several cytokines are known to take part in the 
endothelial dysfunction associated with parasite seques-
tration via induction of intercellular adhesion molecule 
1 (ICAM-1) and endothelial protein C receptor (EPCR) 
expression on the cell surface and also by modulation of 
their shedding in the blood circulation [12, 13]. When 
cleaved from the extracellular domain of the cell mem-
brane, the resulting soluble receptors conserve their 
ability to bind to their cognate ligand and display func-
tions similar to those of cell membrane-anchored coun-
terparts. Therefore, deregulation in the release of these 
receptors may be of pathogenic significance and poten-
tially useful as biological markers of a pathologic condi-
tion. This hypothesis is supported by the results of several 
studies that demonstrated a critical role of soluble recep-
tors and immune mediators in different human diseases, 
including malaria [14–16].
Rapid and accurate diagnosis and effective and prompt 
anti-malarial treatment are the key elements to avoid the 
progression of malarial disease to severe and compli-
cated malaria. Importantly, it is established that immune 
responses and inflammation occur at an early stage of 
P. falciparum infection and result in the secretion of 
numerous measurable biological markers that may serve 
as indicators of the patient’s disease state.
This study aimed to investigate whether and how the 
plasma concentrations of eight soluble bio-molecules, 
namely Neopterin, sCD163, suPAR, Pentraxin3, sCD14, 
Fractalkine/CX3CL1, sTREM-1 and MIG/CXCL9, dif-
fer among young patients presenting with distinct clini-
cal manifestations of malaria. All of these molecules are 
known markers of activation of early immune responses 
and several of them have been directly or indirectly asso-
ciated with P. falciparum in previous studies.
Neopterin belongs to the chemical group known as 
pteridines and reflects the immunological processes 
involving monocytes/macrophages and dendritic cells. 
It is synthesized by macrophages upon stimulation with 
IFN-γ produced by activated T cells and is indicative of 
immune activation [17]. Malaria antigens stimulate neop-
terin secretion and in line with this reaction, patients 
with severe P. falciparum malaria have significantly 
higher levels of this molecule in their plasma [18].
CD163 is a glycoprotein, selectively expressed late 
in the inflammatory reaction on the cell surface of the 
monocyte/macrophage lineage. Increased numbers of 
CD163 positive macrophages have been described in the 
tissue of various inflammatory disorders. High levels of 
the soluble form of the human CD163 receptor (sCD163) 
were found to be associated with severity of malaria in 
Ghanaian children [19]. sCD163 is generated by ectodo-
main shedding of the membrane-bound receptor by pro-
teolysis after oxidative stress or inflammatory stimuli and 
is able to exert anti-inflammatory effects [20].
uPA, the urokinase-type Plasminogen Activator, has 
the capacity to degrade the extracellular matrix by con-
trolled proteolysis. The uPA receptor, uPAR (CD87), is 
central to the interactions between cellular elements and 
the plasminogen activation system. uPAR expression in 
cerebral endothelial cells in CM patients is impaired, and 
the associated lesions have been suggested to contribute 
to an alteration of the blood–brain barrier and immu-
nologic dysfunction in CM patients [21]. uPAR expres-
sion and concentrations of soluble uPAR (suPAR) are 
increased in conditions that involve immune activation 
and inflammation, and suPAR was found to be increased 
in patients with malaria [22].
Pentraxins opsonize pathogens or other particles such 
as dead cells, leading to their phagocytic clearance, and 
induce pathogen killing in extracellular compartments 
[23, 24]. Pentraxin 3 (PTX3/TSG-14) is a pivotal com-
ponent of innate immunity that is rapidly produced in 
response to primary inflammatory signals [25]. PTX3 
acts mainly as a soluble pattern recognition receptor 
(PRR) in the innate immune response [26] and behaves 
as an acute phase response protein (i.e., an inflammatory 
mediator).
The myeloid antigen CD14 is involved in the recog-
nition of a wide variety of bacterial components. It can 
be found either as a membrane-bound (mCD14) or as a 
soluble circulating protein (sCD14), which modulates 
humoral and cellular immune responses by interacting 
with both B and T cells [27, 28]. Elevated serum levels of 
sCD14 have been reported in various inflammatory dis-
eases, including malaria [29].
Fractalkine (CX3CL1) is an atypical chemokine synthe-
sized as a membrane-anchored protein cleaved by metal-
loproteases and shed as CX3CL1 entities in the plasma. 
CX3CL1 is a chemotactic factor for monocytes/mac-
rophages with documented functional roles in the devel-
opment of several inflammatory diseases. In addition, 
it is a key mediator of homeostatic control, with critical 
physiological functions necessary for immune regulation 
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[30]. The membrane-bound form of CX3CL1 could 
mediate the cytoadherence of P. falciparum-infected 
erythrocytes [31].
The triggering receptor expressed on myeloid cells 1 
(TREM-1) is specifically expressed in a subset of neu-
trophils and mature monocytes. This molecule is a 
potent amplifier of pro-inflammatory responses and a 
useful marker for monitoring infectious complications. 
sTREM-1 is the soluble form of the receptor released into 
body fluids by the action of metalloproteases [32] and 
could act as a down-regulator of inflammation [33].
Monokine induced by IFN-γ or Chemokine ligand 
9 (MIG or CXCL9) is a small CXC inflammatory 
chemokine produced by IFN-γ stimulated monocytes, 
macrophages, and endothelial cells. Monocytes and 
macrophages are thought to comprise the majority of 
CXCL9-secreting cells [34], and MIG represents a key 
mediator of innate protective immunity [35, 36].
The examination of how these eight bioactive mol-
ecules are associated with the immune activation that 
occurs during P. falciparum infection and the evaluation 
of their potential usefulness as biomarkers, i.e. as quanti-
fiable parameters that can have an important impact on 
clinical situations with informative potential regarding 
the current state of the malaria-infected patient’s disease 
was performed in this work. These molecules were tested 
for their potential as biomarkers for asymptomatic, 
uncomplicated or severe malaria condition, in Cameroo-
nian young children, and their plasma concentrations 
were found to differ depending on the clinical presenta-
tion of children with falciparum malaria.
Methods
Study design, malaria‑infected patients
After obtaining informed consent from parents or legal 
guardians of children, 5–10 ml of venous blood were col-
lected in ethylenediaminetetraacetic acid (EDTA)-coated 
tubes by venipuncture from different categories of P. fal-
ciparum-infected individuals. The controls consisted of 
plasma samples from 28 healthy French Caucasian blood 
donors. The study was reviewed and approved by the 
Cameroonian National Ethics Committee.
Characteristics of the enrolled patients
A total of 215 plasma samples from children between 
4  months and 12  years of age presenting with distinct 
clinical manifestations of malaria or from asymptomatic 
carriers were considered eligible for the present analy-
sis. The clinical status of each individual was determined 
according to the World Health Organization criteria [37]. 
Four groups were distinguished, including three clini-
cal categories of uncomplicated malaria, severe malaria, 
and cerebral malaria and one group of asymptomatic 
carriers. The group of cerebral malaria was character-
ized by homogeneity of clinical symptoms (presence of 
seizures without other complications of severe malaria). 
Therefore, this group was extracted from that of severe 
malaria.
Blood collection procedures
Asymptomatic Plasmodium falciparum malaria carriers (AM)
Cameroonian school children were mass-screened to 
detect parasite carriers. Thick blood smears from finger-
pricked samples were stained with 10  % Giemsa, and 
the number of P. falciparum parasites was determined 
by microscopy. After blood smear examination, samples 
with gametocytes, mixed infections with Plasmodium 
ovale and/or Plasmodium malariae, and from children 
who had axillary temperature >37.5  °C were excluded 
from this group. Samples from 80 children less than 
12  years of age with positive P. falciparum thick blood 
smears who had not taken any anti-malarial treatment 
within the previous 2  weeks and who did not present 
with fever at the time of enrolment and during the previ-
ous 3 days were admitted to this group.
Children with >1000 asexual parasites/μl and signs 
and symptoms associated with malaria were treated with 
artesunate–amodiaquine, as recommended by the Cam-
eroonian Ministry of Public Health.
Uncomplicated malaria (UM) patients
Sixty-nine symptomatic children consulting at the 
Nlongkak Catholic missionary dispensary in Yaoundé for 
febrile episodes were enrolled in the study. The inclusion 
criteria in this group were parasitaemia ≥0.1  %, fever 
(rectal temperature ≥38.0 °C), absence of other Plasmo-
dium species, denial of recent self-medication with an 
anti-malarial drug, and absence of signs and symptoms 
of severe and complicated malaria. After blood sampling, 
the enrolled patients were treated with artesunate–amo-
diaquine or artemether–lumefantrine. Blood samples of 
39 UM children less than 5  years of age were collected 
28 days after malaria treatment and recovery.
Severe malaria (SM)
Forty-one symptomatic children aged less than 4  years 
were recruited at Olembe Health Centre, Yaoundé, if 
they presented with one or more of the following signs 
and symptoms of severe and complicated malaria: pul-
monary oedema, acute respiratory distress syndrome, 
acute kidney failure, abnormal liver function, massive 
destruction of red blood cells associated with dark-
colored urine (haemoglobinuria), or severe anaemia 
(defined as either a haemoglobin level of <5  g/dl or a 
haematocrit of <15 %). All children in the SM group had 
Blantyre score ≥4.
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Cerebral malaria (CM)
Twenty-five children aged less than 4 years were enrolled 
with a Blantyre coma score of <2 persisting for 30  min 
and/or at least two seizure episodes within 24 h, with no 
other obvious causes of coma. Lumbar puncture was sys-
tematically performed to exclude meningitis. Children 
were given the appropriate treatment, as recommended 
by the Cameroonian Ministry of Public Health.
Individual data including age, sex, weight, clinical his-
tory, physical and neurological examinations (Blantyre 
coma score), parasitaemia, and blood biochemistry (cre-
atinine, C-reactive protein) were recorded in an ad-hoc 
data form. In all cases, data were treated anonymously by 
replacing names by codes to insure confidentiality and 
blindness of laboratory analysis.
ELISA protocols
All plasma samples were assayed in duplicate blindly. 
Standard ELISA experiments were performed accord-
ing to the manufacturer’s instructions (DuoSet® ELISA 
Development System, R&D Systems, Minneapolis, MN). 
Briefly, plasma samples were diluted 1:1000 for sCD14, 
1:80 for sCD163, 1:40 for Fractalkine, 1:10 for uPAR and 
Pentraxin, 1:2 for sTREM-1 and MIG and undiluted for 
Neopterin. Neopetrin level was tested in a competition 
ELISA test from IBL International R (Hamburg, Ger-
many). The competition was evaluated between a perox-
idase-conjugated and non-conjugated antigen for a fixed 
number of coated anti-Neopterin antibody binding sites. 
Unbound antigen was removed by washing, and the opti-
cal density (OD) was measured after substrate reaction. 
When the obtained OD values were out of the standard 
reference range, dilutions were modified accordingly.
In all experiments, analyte concentrations were cal-
culated according to standard curves obtained by the 
assessment of specific recombinant human proteins 
elaborated by the manufacturers and determined in each 
ELISA plate, which systematically included negative con-
trol sera. The final results were expressed as ng/ml, with 
the exception of Fractalkine concentrations, which were 
expressed as pg/ml.
Statistical procedures
Since data distribution was not Gaussian, numerical val-
ues were expressed as median and interquartile ranges 
(IQR). The values of each plasma protein were trans-
formed using a logarithmic function in order to approach 
normal distribution within disease groups and stabi-
lize the variances. According to Bonferroni correction, 
because the number of univariate tests (median tests) 
used to compare two clinical conditions included eight 
analytes, it may be better to consider a p value <0.006 as 
a more relevant threshold of significance than a p value 
<0.05.
Stepwise multivariate analyses were carried out using 
logarithm-transformed values for each analyte and this 
methodological approach, as well as principal component 
analysis (PCA), was used to limit the number of statisti-
cal tests. PCA was used to cluster variables according to 
their group because PCA captures differences between 
groups by extracting dominant patterns from data 
matrix. For PCA analyses, raw data were standardized 
by subtracting the mean value of a given mediator from 
each individual analyte concentration and by divid-
ing the result by the standard deviation [standardized 
value =  (value − mean)/SD]. Therefore, PCA was inde-
pendent of the rescaling carried out for each soluble pro-
tein tested.
The diagnostic accuracy of the biomarkers was assessed 
using receiver operating characteristic (ROC) curve anal-
ysis. ROC curve analyses were used to test the capacity 
of individual parameter concentrations to discriminate 
between clinical groups. The ROC curve is a two-dimen-
sional measure of classification performance where the 
area under the ROC curve (AUROCC) accurately meas-
ures discrimination, i.e., reflects the power of a quantified 
parameter to distinguish between two clinical groups. 
The greater the AUROCC, the better the test is. The 
accuracy of this diagnostic test was classified according 
to the traditional academic point system where: 0.90–1 
is excellent, 0.80–0.9 is moderate, and 0.7–0.8 is fair. 
The closer the ROC curve is to the upper left corner, the 
higher the overall accuracy of the test [38].
Results
Characteristics of the enrolled subjects
The mean age (±SD) of sixty-nine children with acute 
uncomplicated malaria (UM), including 39 children 
recovering from UM syndrome and tested 28 days after 
the initial blood sampling (UM-28), was 2.9 ± 1.6 years. 
The mean ages (±SD) of 41 children with severe malaria 
(SM) and 25 cerebral malaria patients (CM) were 
3.2 ± 3.3 and 2.3 ± 2.5 years, respectively. The mean age 
(± SD) of 135 symptomatic children (3.1 ± 2.6 years) was 
significantly lower than that of 80 asymptomatic parasite 
carriers (AM) (6.3 ± 1.1 years; p < .0001). There was no 
deliberate selection of the children enrolled in this study 
based on age, but the mean age of patients with distinct 
clinical presentations differed significantly (p < 0.05).
Plasma concentrations of bioactive molecules
As shown in Table  1, compared to control (CTS), AM 
group displayed similar median concentrations of suPAR 
and a slight decrease in sTREM-1 whereas the median 
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plasma level of PTX3 was 12.3 times lower in this group. 
Plasma concentrations of Neopterin, sCD163, sCD14 and 
MIG were significantly increased in AM, and the median 
concentration of Fractalkine in AM children was 1.87-
fold higher than in CTS (p < 0.0001).
Compared to the median CTS values, patients in the 
UM group displayed both the highest median level of 
sCD14 (5.4-fold increase) and a higher median value of 
PTX3 (7.1-fold increase) with p values <0.0001. In con-
trast, the median sCD163 and Fractalkine levels in UM 
and AM groups were similar (with a 2.2- and 1.3-fold 
increase compared to CTS, respectively).
On day 28 after malaria treatment and recovery, plasma 
levels were similar to those of controls for the majority of 
biomarkers tested, with the exception of the median values 
of sCD14 (p = 0.0003) and Fractalkine (p < 0.0001), which 
were lower than the corresponding median CTS levels.
In the SM group, plasma samples were singled out 
by a marked rise of Neopterin, suPAR, and PTX3 
median contents that were increased 3.2-, 2.0- and 
4.3-fold, respectively, compared to the corresponding 
median CTS results (all p values <0.0001). sTREM-1 
was marginally raised (1.1-fold) whereas the Frac-
talkine median level was 5.1 times lower than the CTS 
levels (p  <  0.0001). Compared to that of UM children, 
plasma from SM children displayed a higher median 
level of Neopterin (with a 3.4-fold increase), a 6.8-fold 
decrease of the median Fractalkine, a 3.9-fold decrease 
of the median sCD14 value, and lower median values of 
sCD163 and PTX3 (with a 1.4- and a 1.7-fold decrease, 
respectively). All p values were less than 0.0001 except 
for PTX3 (p = 0.054).
Children in the CM group were characterized by a 
dramatically elevated PTX3 median level (6.9 times) 
and moderately increased median levels of suPAR (2.0-
fold) and MIG (2.1-fold) by comparison with the corre-
sponding CTS values. Compared to UM children, plasma 
samples from CM children showed modestly increased 
median concentrations of suPAR (1.2-fold) and MIG 
(1.6-fold) (p  >  0.05). In contrast, significantly increased 
levels of Neopterin (3.2-fold) and sTREM-1 (1.6-fold) and 
markedly decreased median levels of sCD14 (5.8-fold) 
and Fractalkine (6.7-fold) were found in the CM group 
(p < 0.0001).
When the median plasma content of SM patients was 
compared to that of CM patients, no major difference 
was detected, except for a slightly increased median 
value of PTX3 (1.6-fold, p =  0.385) and MIG (1.3-fold, 
p = 0.0235) in children with CM. A trend for a decrease 
in sCD14 levels was detected in CM compared to SM 
patients (median test, p = 0.0293) but none of the p val-
ues were less than 0.006. Therefore, there was no statis-
tically significant difference detectable between CM and 
SM children in the median plasma levels of 7 of the 8 bio-
markers tested, suggesting that none of the biomarkers 
used in the present study were capable of distinguishing 
between SM and CM.
Correlations between analyte concentrations
As shown in Table  2, the strongest positive correlations 
were found between sTREM-1 and Neopterin (R = 0.642) 
and between sTREM-1 and suPAR (R = 0.448), whereas 
Fractalkine was negatively correlated with Neopterin and 
suPAR (R = −0.420 and −0.463, respectively). In addition, 
a positive correlation was observed between MIG and 
Neopterin, and MIG and sTREM-1 (R = 0.435 and 0.401, 
respectively). PTX3 was also positively correlated with 
sTREM-1 and suPAR (R = 0.368 and 0.354, respectively).
Pattern of changes in plasma analyte concentrations 
among patients with different clinical conditions
Compared to control values, the relative fold changes in 
biomarker concentrations were determined in different 
groups of children with malaria infection. Figure 1 shows 
that the ratio of concentration of several analytes fol-
lowed a comparable trend. For example, MIG, sCD163, 
suPAR and sTREM-1 displayed a similar pattern of 
fold changes in different clinical syndromes. PTX3 and 
sCD14 as well as Neopterin and Fractalkine fold changes 
were comparable in 3 of 5 clinical conditions. However, 
Table 2 Correlations between the plasma concentrations of the eight different soluble mediators
Correlations were estimated by the restricted maximum likelihood (REML) method using JMP®
sCD14 sCD163 Fractalkine Neopterin sTREM‑1 MIG suPAR PTX3
sCD14 1
sCD163 0.147 1
Fractalkine 0.272 0.208 1
Neopterin −0.094 −0.024 −0.420 1
sTREM-1 0.035 0.068 −0.310 0.642 1
MIG 0.048 0.118 −0.026 0.435 0.401 1
suPAR 0.043 0.122 −0.463 0.379 0.448 0 234 1
PTX3 0.192 0.125 −0.019 0.168 0.368 0.246 0.354 1
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plasma PTX3 and Neopterin were characterized by 
sharply increased ratios in SM and CM patients whereas 
the ratios of fold changes of sCD14 and Fractalkine were 
consistently low in these two clinical conditions. Figure 2 
illustrates the pattern of fold changes of each biomarker 
according to the clinical condition.
Plasma biomarker concentrations and blood parasitaemia
The results of a stepwise multivariate analysis showed 
that, when controlling for age and plasma levels of the 
eight biomarkers, parasitaemia was positively correlated 
with PTX3 plasma concentrations (R = 0.444; p < 0.0001).
Compared to the other biomarkers tested, the pat-
tern of Neopterin distribution was bimodal, which led to 
check whether the distribution of this analyte concentra-
tion in the plasma was linked to a particular level of other 
available parameters, such as age and parasitaemia. When 
considering two subgroups with Neopterin values either 
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Fig. 1 Fold changes in the plasma levels of eight biomarkers illustrating similar trends between various pairs of biomarkers in distinct clinical 











































Fig. 2 Patterns of plasma level fold changes observed for each 
biomarker in different malaria clinical conditions
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differentiated the bimodal Neopterin distribution), plasma 
samples from younger children (mean ± SD, 3.2 ± 3.4 years 
old) contained a higher level of Neopterin than those 
from older children (mean  ±  SD, 4.1  ±  2.1  years of age; 
p = 0.0244). Plasma samples with Neopterin values ≤5.5 ng/
ml were associated with a mean (±SD) parasitaemia level of 
29,882 ± 75,364 asexual parasites/µl, whereas plasma sam-
ples with Neopterin level >5.5 ng/ml were found in patients 
with a mean parasitaemia level of 76,280 ± 102,198 asexual 
parasites/µl (median test, p = 0.0039).
Compared to plasma samples with high Neopterin 
content, those with Neopterin levels ≤5.5  ng/ml were 
associated with significantly higher mean sCD14 con-
centration (10,496 ±  17,695 versus 3856 ±  2390  ng/ml; 
median test p  <  0.0001), lower sTREM-1 concentration 
(0.29 ± 0.09 versus 0.52 ± 0.08 ng/ml; p < 0.0001), lower 
suPAR concentration (5.2  ±  1.8 versus 8.0  ±  2.3  ng/
ml; p < 0.0001), lower PTX3 concentration (12.2 ± 22.8 
versus 20.1 ± 16.6 ng/ml; p = 0.0002), and higher Frac-
talkine concentration (92.6 ± 45.6 versus 15.2 ± 11.0 pg/
ml; median test p < 0.0001) levels.
Clustering analysis
The relationship between the plasma levels of eight bio-
markers and the malaria clinical groups to which the 
children were assigned was evaluated by hierarchical 
clustering. Plasma concentrations from treated and cured 
children 28 days after an UM episode were, as expected, 
close to healthy control subjects (distance  =  1.11), and 
the latter were at some distance from AM children (dis-
tance  =  2.35). UM patients were farther away from 
healthy controls (distance = 3.45), and the groups of chil-
dren with SM and CM were at a greater distance from 
healthy controls (distance  =  4.52). Consistent with the 
similarity of median values obtained for most biomark-
ers, SM patients were very close to CM patients (dis-
tance = 0.96) as illustrated in Fig. 3, confirming that the 
plasma bio-proteins tested were not useful to differenti-
ate between these two clinical syndromes.
Biomarkers discriminating AM from UM group
The accuracy of plasma biomarker levels to discriminate 
between the CTS and AM children was evaluated by 
ROC analysis [39, 40] as indicated in Table  3. The area 
under the ROC curve reflects the ability of each indi-
vidual analyte measurement to discriminate between 
individuals with distinct clinical conditions. ROC curves 
showed that Fractalkine and sCD163 were the most use-
ful analytes to distinguish between CTS and AM groups. 
The Area Under the Curve (AUC and 95  % confidence 
interval) was 0.985 [0.562–1.000] and 0.959 [0.922–
0.996] for Fractalkine and sCD163, respectively.
PTX3 (AUC = 0.979 [0.958–0.999]) and suPAR (0.958 
[0.922–0.994]) were most useful to distinguish UM from 
AM children with p values <0.0001 in each case, whereas 
sCD163, Fractalkine, Neopterin, and MIG did not dis-
criminate between UM and AM children (Table 4).
Biomarkers discriminating SM and CM from UM patients
When SM patients were compared to CM patients with 
each of the eight biomarkers selected for this study, 
the corresponding ROC curves failed to discriminate 
between the two clinical conditions. Therefore, for subse-
quent analysis, these two clinical categories were grouped 
together as patients with SM–CM condition.
When children with SM–CM were considered as 
the positive test group and compared to UM children, 
Neopterin (AUC  =  1.000 [1.000–0.000]) and sTREM-1 
(AUC = 0.957 [0.919–0.994]) were the best discriminat-
ing biomarkers (p < 0.0001). The lowest AUC values were 
found for sCD14 and Fractalkine because the concentra-
tions of these two analytes were sharply reduced both 
in CM and SM patients, compared to the plasma levels 
found in UM children.
Principal component analyses results
Principal Component Analysis (PCA) was used to iden-
tify the principal components of data and evaluate the 
potential link(s) between the biomarkers and malaria 
clinical groups. PCA successfully characterized linear 
combinations of different markers tested that allowed 
the identification of a specific “biomarker profile” and 
determined marker associations corresponding to vari-
ous clinical conditions. A general trend is illustrated 
in Fig.  4a where all the available rescaled values of the 
plasma biomarker levels were tested together and where 
the main clinical malaria conditions appeared spread out 
in the biplot. AM children, with no clinical expression of 
malaria infection, were mostly grouped on the lower left 
part of the biplot, and most of the UM patients were pre-
dominantly spread in the upper left part of the biplot. It is 
worthy of note that Fig. 4a shows again that SM and CM 
patients could not be differentiated with the biomarkers 
Dendrogram
Fig. 3 Result of clustering analysis. A hierarchical classification 
obtained by Ward method is illustrated as a dendrogram, and indica-
tions of distance between clusters are as follows: ACT (controls)- 
UM + 28 = 1.11; ACT-AM = 2.351; ACT-UM = 3.452; ACT-SM = 4.517; 
SM–CM = 0.961
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used and SM–CM patients are located in the right part 
of the biplot, clearly away from AM children and UM 
patients.
Fractalkine, MIG, and Neopterin delineated a clus-
ter associated with the AM condition whereas PTX3 
was negatively associated with asymptomatic carriage 
(Fig.  4b; Table  4). suPAR, PTX3, and sTREM-1 were 
strongly associated with the UM condition, i.e. with mild 
to moderate severity of illness, whereas Neopterin and 
Fractalkine were negatively associated with this condi-
tion (Fig.  4c; Table  4). Finally, Neopterin and sTREM-1 
were associated with the most severe condition of clinical 
malaria in children, i.e. they were associated with SM–
CM patients, whereas Fractalkine was negatively associ-
ated with this condition (Fig. 4d; Table 4).
Discussion
In the present study, the relevance of eight bio-pro-
teins present at varying concentrations in the plasma of 
young children was investigated to characterize differ-
ent clinical syndromes of malaria. From a clinical per-
spective, the progression from asymptomatic malaria 
condition to uncomplicated illness and then to severe 
malaria [41] implicates host factors, including mono-
cytes/macrophage activators. The hypothesis that the 
plasma concentration profile of these analytes may be 
useful to assess the progression of the disease sever-
ity and may reflect pivotal physiopathological processes 
involving inflammation and tissue damage in young 
malaria-infected patients is plausible. Indeed, the valida-
tion of reliable biomarkers for early diagnosis of severe 
Table 3 Assessment by ROC curve analyses of the individual prediction performance of each of the eight plasma proteins 
to differentiate between clinical malaria conditions
Plasma levels of eight proteins were quantified in 80 AM children, 69 UM patients and 66 SM or CM patients. Receiver operator characteristics (ROC) curves were used 
to estimate the power of each of the eight mediators to individually distinguish between two distinct clinical malaria conditions. Results of ROC curve analyses are 
indicated for AM children versus Controls (A), UM patients versus AM children (B) and SM–CM versus UM patients (C)
Test result variables AUROCC ± Std error Asymptomatic 95 % lower bound Asymptomatic 95 % upper bound
A
 Fractalkine 0.985 ± 0.015 0.956 1.000
 sCD163 0.959 ± 0.019 0.922 0.996
 Neopterin 0.857 ± 0.050 0.760 0.954
 sCD14 0.842 ± 0.049 0.745 0.939
 MIG 0.788 ± 0.062 0.666 0.910
 sTREM-1 0.605 ± 0.081 0.446 0.764
 suPAR 0.485 ± 0.075 0.337 0.632
 Pentraxin 0.233 ± 0.05 0.135 0.331
B
 Pentraxin 0.979 ± 0.010 0.958 0.999
 suPAR 0.958 ± 0.018 0.922 0.994
 sCD14 0.876 ± 0.030 0.817 0.936
 sTREM-1 0.832 ± 0.037 0.759 0.905
 sCD163 0.499 ± 0.053 0.395 0.602
 MIG 0.490 ± 0.053 0.387 0.593
 Fractalkine 0.314 ± 0.049 0.218 0.410
 Neopterin 0.246 ± 0.049 0.149 0.343
C
 Neopterin 1.000 ± 0.000 1.000 0.000
 sTREM-1 0.957 ± 0.019 0.919 0.994
 suPAR 0.678 ± 0.053 0.575 0.782
 MIG 0.566 ± 0.069 0.431 0.702
 Pentraxin 0.401 ± 0.053 0.297 0.504
 sCD163 0.308 ± 0.049 0.213 0.404
 sCD14 0.100 ± 0.027 0.047 0.154
 Fractalkine 0.000 ± 0.000 0.000 0.000
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life threatening malaria infections would also contribute 
to improving the identification and case management of 
patients at risk of death.
Biomarker concentration profile in AM children
The results show that in the AM group, i.e. in children 
with clinical immunity and a state of parasite tolerance 
that protects them from disease expression but not 
from malaria infection, the lowest levels of blood par-
asitaemia were detected. Compared to controls, AM 
children displayed simultaneously raised sCD163 
plasma content and the highest level of Fractalkine. 
These two molecules are involved in immune response 
down-regulation (for sCD163) and in the modulation of 
inflammatory responses (for Fractalkine). On the one 
hand, sCD163 is linked to states of low-grade inflam-
mation [42], and on the other hand, Fractalkine plays a 
critical role in immunoregulation of myeloid cell acti-
vation [43]. Given that sCD163 down regulates inflam-
matory responses, it was surprising to find that sCD163 
was strongly predictive of the asymptomatic condition 
by ROC analysis but not by PCA investigation. This is 
the only unexpected result with the two methods used 
in this study, and no rational explanation for this dis-
cordant observation was found.
Fractalkine/CX3CL1-CX3CR1 interactions confer an 
essential survival signal to monocytes via anti-apoptotic 
mechanisms [44] and directly promote monocyte anti-
inflammatory and anti-procoagulant responses through 
inhibition of Tissue factor (TF) expression [30]. As TF 
is a major pro-inflammatory mediator, this observation 
is suggestive of a favorable contribution of Fractalkine in 
decreasing the negative impact of parasite infection and 
reducing or slowing the development of illness [45]. This 
might occur through the involvement of Fractalkine in 
a form of tolerance to low parasitaemia, as suggested in 
this study by the dramatic decrease of Fractalkine levels 
in plasma samples of children with SM or CM, compared 
to the UM and AM groups.
Neopterin is an early marker of immune activation that 
reflects various interactions of immunocompetent cells. 
Its level was slightly raised in AM children compared to 
CTS, most likely indicating that an immunological pro-
cess was going on under controlled conditions in asymp-
tomatic parasite carriers.
Of note, AM children had the lowest level of PTX3, 
a protein involved in inflammatory responses of both 
non-infectious and infectious origin and known to limit 
harmful inflammatory reactions [46]. The concentration 
of this protein was found to be lower in AM children 
than in controls, suggesting that inflammatory responses 
were contained and controlled in AM children in parallel 
with a decrease of this acute-phase protein.
Similarly, sTREM-1, which is an effective marker for 
chronic exacerbated inflammation [47, 48], was also 
lower in AM children than in control samples, possibly 
reflecting controlled inflammatory conditions in these 
individuals.
In addition to Fractalkine, MIG/CXCL9 and Neopterin 
were also strongly linked to AM condition based on PCA 
Table 4 Assessment by  principal component analyses 
of the association between eight plasma proteins and clin-
ical malaria condition
The main associations found between biomarkers and clinical outcomes using 
rescaled variables for PCA analyses are indicated and sorted out for each clinical 
malaria condition
The combination of Fractalkine, MIG/CXCL9 and neopterin was the best 
predictor of AM condition (A). The combination of suPAR, PTX3 and sTREM-1 was 
the best indicator of the UM condition (B) whereas that of neopterin, suPAR and 
Fractalkine was strongly predictive of SM–CM conditions (C)
In each Table, two columns (Factor 1 and 2) indicate the correlation coefficients 
determined between each vector and the main component. Eight values 
are associated with vectors and the proportion (%) reflects how much of the 
variance is explained by each vector. The last column indicates the cumulative 
percentage of the variance explained by the different vectors sorted out by 
decreasing order of the corresponding eigenvalues







 Fractalkine 0.85545 −0.11784 3.3656 42.070 42.070
 MIG 0.73788 0.39620 1.1835 14.793 56.863
 Neopterin 0.70432 −0.43758 1.0940 13.676 70.539
 CD14 0.62246 −0.25274 0.7673 9.592 80.130
 sTREM-1 0.56695 0.61686 0.6733 8.417 88.547
 CD163 0.53826 0.23644 0.4064 5.080 93.627
 suPAR 0.10568 0.46070 0.3428 4.286 97.913
 PTX3 −0.76387 0.32950 0.1670 2.087 100.000
B
 suPAR 0.88028 0.03387 2.5280 31.600 31.600
 PTX3 0.76330 −0.15305 1.2911 16.139 47.738
 sTREM-1 0.74615 −0.13346 1.1018 13.773 61.511
 sCD14 0.34031 −0.46342 0.8155 10.193 71.705
 sCD163 0.32028 0.63252 0.7944 9.930 81.635
 MIG 0.06559 0.44941 0.6824 8.529 90.165
 Neopterin −0.43095 0.33440 0.4736 5.920 96.085
 Fractalkine −0.45310 −0.56576 0.3132 3.915 100.000
C
 Neopterin 0.93285 −0.17805 3.1726 39.658 39.658
 sTREM-1 0.76040 0.18134 1.2971 16.214 55.871
 suPAR 0.57427 0.57156 0.9591 11.988 67.860
 MIG/
CXCL9
0.48202 0.36299 0.8547 10.684 78.544
 PTX3 −0.14160 0.69833 0.7624 9.530 88.074
 sCD163 −0.29783 0.47885 0.5191 6.489 94.563
 sCD14 −0.47978 0.17089 0.3726 4.658 99.221
 Fractalkine −0.90726 0.16699 0.0623 0.779 100.000
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results. MIG is a critical immune effector molecule with 
the potential to promote TNF-α in  vivo [49]. The bio-
synthesis of Neopterin is closely associated with activa-
tion of the cellular immune system, and it is a sensitive 
indicator of Th1-derived cellular immune activation. It 
is linked with the general level of immune activation and 
the extent of oxidative stress, but is negatively correlated 
with IL-10. Its secretion is stimulated by malaria antigens 
[18]. This bio-substance is involved in the systemic pro-
inflammatory response of the host to invading patho-
gens and likely suggests here a detectable immunological 
response in AM children.
a b
c d
Fig. 4 Biplots illustrating the main results of PCA analyses. a Shows that all SM and CM patients are grouped on the right part of the biplot whereas 
uncomplicated clinical conditions, i.e. patients with less severe syndromes, are located on the upper left part of the biplot. Conditions of asympto-
matic carriage, i.e. situations without clinical expression of the disease, are found in the lower left quarter of the graph of scores. The combination 
of Fractalkine, MIG/CXCL9 and neopterin was the best predictor of AM condition versus that of controls (b). The combination of suPAR, PTX3 and 
sTREM-1 was the best indicator of the UM condition versus AM syndrome (c) whereas that of neopterin, suPAR and Fractalkine was strongly predic-
tive of SM–CM compared to UM condition (d)
Page 12 of 15Tahar et al. Malar J  (2016) 15:337 
Biomarker concentration profile in UM children
Through cleavage of uPAR by uPA or other proteases, 
the most likely sources of suPAR in  vivo remain acti-
vated monocytes and endothelium. suPAR is a marker of 
monocytes and immune response activation which, by its 
interaction with uPA, operates as an endogenous anti-
biotic [50] via the activation of neutrophil granulocytes, 
leading to microbe destruction by superoxide mecha-
nisms [51, 52]. This level increases when TNF concen-
tration is raised, and the plasmatic levels of suPAR were 
previously found to be increased in several infectious 
diseases, including malaria [51, 53]. The uPA–uPAR sys-
tem might also modulate several steps of the inflamma-
tory cascade, facilitate the recruitment of effector cells at 
the site of infection, and thereby control the clearance of 
infectious pathogens and remodeling of damaged tissues. 
Overall, suPAR is involved in complex biological func-
tions, including innate immune defense and regulation of 
inflammation.
PTX3 regulates the activity of cells of the immune sys-
tem and dampens exacerbated inflammation [54]. This 
component reached its highest circulating median value 
in UM patients. PTX3 is linked to the development of a 
protective Th1/Treg immune response but also limits 
the harmful inflammation elicited by Th17/Th2 immune 
response [55]. This is suggestive of a critical contribu-
tion to limitation of exaggerated inflammatory responses 
in the group of UM patients. PTX3/TSG-14 production 
is induced by pathogen recognition, facilitates cellular 
recognition by phagocytes and was reported to be one 
of the neutrophil extracellular traps (NETs) component 
proteins involved in pathogen recognition and clearance 
[56]. Of note, PTX3 is also an enhancer of the expression 
of tissue factor by activated monocytes [57]. It is strik-
ing to observe that the amount of this plasma bio-pro-
tein was so markedly increased in UM patients and CM 
patients.
Plasma from UM children contained the highest level 
of sCD14, which resulted from an increased membra-
nous CD14 shedding that plays a key role in the neu-
tralization of lipopolysaccharides by antagonizing TNF 
[58] and reflects an activated status of monocytes or 
macrophages. The liver is also one of the major sources 
of sCD14 [59], and it was suggested that sCD14 might 
preserve liver function through down-regulation of the 
inflammatory cascade [58]. It is also established that 
CD14 signaling is essential for long p38-MAPK/SOCS 
activation that limits and relieves inflammation through 
the induction of tolerance [60]. Of note, TF expres-
sion was previously found to be correlated with markers 
of immune activation, including sCD14 [61], but high 
amounts of circulating sCD14 are also known to buffer 
inflammatory signals by avoiding their exposure with 
monocyte- and macrophage-anchored CD14 [62]. Over-
all, raised levels of plasma sCD14 might regulate both the 
intensity and duration of host responses to pathogens 
and could contribute to protect the UM patients from 
harmful inflammatory consequences.
In UM children, sCD163 and Fractalkine median levels 
were similar to those found in AM children, in agreement 
with the mild clinical manifestation of uncomplicated 
malaria compared to more severe conditions found in 
SM–CM patients. Remarkably, the Neopterin level of 
UM children was intermediate between that of the con-
trols and that of AM children, suggesting the limited 
number, if not the virtual absence, of highly activated 
T cells which are the cells that produce IFN-γ, the only 
known stimulant of Neopterin biosynthesis [63].
Biomarker concentration profile in SM–CM patients
A high concentration of Neopterin was detected in the 
plasma of young SM–CM patients, indicating either an 
overall sustained state of inflammation or the contri-
bution of this pteridine in inflammatory processes by 
stimulation of the nuclear factor-κb. High plasma Neop-
terin levels are related to increased cell-mediated immu-
nity and macrophage activation, and they were found 
to remain elevated in patients with persistent anaemia 
after treatment of severe malaria [64]. Neopterin was 
also found to be correlated with the degree of anaemia in 
Zambian children with either cerebral or severe malaria 
[65]. In agreement with this previous observation, our 
analysis showed that children with SM and/or CM had 
the highest levels of plasma neopterin. Depending on its 
level, neopterin could be beneficial to the host at low lev-
els in AM children, but detrimental in high amounts in 
SM and CM patients.
Even if the median sTREM-1 plasma content was only 
slightly increased in SM–CM patients, it may have con-
tributed to amplify the inflammatory responses. Dynamic 
changes of plasmatic sTREM-1 level have been suggested 
to be useful to assess the severity of sepsis and predict the 
prognosis of its treatment [66–69]. Whereas the quanti-
fication of sTREM-1 alone was not found useful to dif-
ferentiate SM from UM patients in a previous study [70], 
sTREM-1 in association with neopterin appeared more 
relevant to discriminate severe malaria syndromes from 
uncomplicated presentations in children, as illustrated in 
Tables 3 and 4 and Fig. 4d.
An elevated level of suPAR was associated with a poor 
outcome in patients with severe malaria [70]. In that 
previous study, the use of this molecule as a marker of 
malaria-associated pathology was recommended. In the 
Cameroonian children of the present study, this protein 
increased gradually from AM to UM and to SM–CM 
conditions. It is plausible that inappropriate activation of 
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the uPA system could contribute to persistent inflamma-
tion and favor pathological manifestations [71].
Patients with either SM or CM condition had lower 
levels of sCD14 than UM, and this may have contributed 
to drive them towards these immuno-pathological states. 
Fractalkine/CX3CL1 median levels were the lowest found 
among P. falciparum infected children, suggesting a pos-
sible loss of tissue inflammation control in the absence of 
this key immune regulator. Fractalkine also possesses the 
capacity to induce platelet activation and adhesion via a 
functional Fractalkine receptor (CX3CR1) expressed on 
the platelet surface. This physiological mechanism might 
be progressively limited when Fractalkine concentra-
tions decrease gradually in malaria-infected patients with 
increasing disease severity. To some extent, this might 
explain why no fatal outcome was observed in malaria-
infected patients enrolled in this study, a situation which 
illustrates a key difference between severe malaria in chil-
dren and adults [22].
In severe falciparum malaria syndromes, as in many 
other systemic infections, most of the pathological dam-
ages seem to result from an intense inflammatory burst, 
facilitated by a pathological activation of the immune sys-
tem and proinflammatory cytokine release [72, 73]. The 
high concentrations of Neopterin, sTREM-1, and suPAR 
and their potential as indicators of severe inflammatory 
conditions are in agreement with this hypothesis.
Conclusions
Fractalkine and sCD163 were singled out in AM children, 
whereas plasma PTX3 seemed relevant only in UM chil-
dren. It is possible that these markers could have contrib-
uted to a specific modulation of inflammatory and innate 
immune responses in AM and UM malaria presentations 
and not in SM and CM conditions, but this observation 
remains to be confirmed by further studies.
Combination of several biomarkers is known to pre-
dict mortality in severe malaria [74]. As suggested by the 
analyses, and regardless of whether the host biomark-
ers mediate or simply reflect pathology, combinations 
of various soluble proteins were found to be relevant as 
potential diagnostic tools to differentiate malaria clini-
cal presentations in children. Ideal biomarkers are those 
that are associated with clinical endpoints in obser-
vational studies, but it is established that evolution of 
asymptomatic carriage to uncomplicated malaria and to 
severe and complicated malaria can occur rapidly, nota-
bly in children. Therefore, such ideal bio-indicators may 
be difficult to identify for an accurate characterization 
of malaria patients. Further investigations with a higher 
number of cases including adult patients and additional 
biomarkers might be useful to validate some of the pre-
sent findings and better differentiate SM from CM 
clinical conditions which are frequently considered as a 
single entity [75]. They may provide useful insights into 
the functional role of some of these bioactive molecules 
in the complex host-parasite relationship and in malaria 
pathology.
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